Skip to main content Skip to search Skip to main navigation

EMA: Update of the GACP Guideline Published

The guideline on Good Agricultural and Collection Practice (GACP) for herbal starting materials has been in place since 2006 to ensure consistent quality of herbal substances. The newly released Revision 1 updates the document to current standards, reflecting developments over the past decade such as the growing use of indoor cultivation technologies and published legal interpretations. In addition, Annex 1 introduces specific requirements for indoor cultivation practices.

Indoor cultivation facilities should contain adequate systems for air, climate and humidity control, light, water treatment, ventilation and air filtration systems. They are designed to:

  • Control access to personnel;
  • Minimise potential contamination;
  • Facilitate cleaning, maintenance and other operations;
  • Be impermeable to cleaning and disinfecting agents.

For documentation, the new Annex 1 stipulates:

  • Documentation of all relevant conditions, materials, and processes
  • Batch-specific acceptance criteria for cultivation & production
  • SOP-based document management including retention rules
  • Product specifications per batch defined and recorded
  • Cleaning activities documented in batch records/logbooks
  • Daily digital records of critical process parameters for indoor cultivation

Regarding crop maintenance and plant protection, Annex 1 stipulates:

  • Written procedures for material receipt, storage, handling, sampling, approval/rejection
  • Validation of processes, cleaning, and responsibilities documented
  • Calibration of all cultivation equipment per schedule
  • Material approval before each new cultivation cycle by QA
  • Indoor cultivation: Identify critical quality attributes (CQA) & process parameters (CPP)
  • Define in-process criteria and controls
  • Standardize cultivation process
  • Complete qualification of critical equipment and supporting systems

Source:

EMA: Good agricultural and collection practice for starting materials of herbal origin - Scientific guideline


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA and PIC/S have published a concept paper announcing a targeted revision of Annex 6 Manufacture of Medicinal Gases of the EU GMP Guide. The last update dates from 2010. The revision aims to reflect current manufacturing practice, technological progress and lessons learned from the COVID-19 pandemic.

Read more
EMA: Concept Paper on the Revision of Annex 15

EMA: Concept Paper on the Revision of Annex 15

EMA and PIC/S have published a concept paper outlining a targeted revision of Annex 15 (Qualification and Validation).

Read more
What do Typical Manufacturing Processes for Sterile Products look like?

What do Typical Manufacturing Processes for Sterile Products look like?

Here's the answer:
Read more
Human Resource Management as a Key to Success

Human Resource Management as a Key to Success

The pharmaceutical industry in Germany and other countries, too, faces considerable challenges in the area of human resource management. These problems have far-reaching implications for the competitiveness and innovative power of the industry.

Read more
EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

The EMA has published a new reflection paper outlining its current thinking on the qualification of non-mutagenic impurities (NMIs). The paper addresses recommended approaches for evaluating the safety of new or increased impurity levels, particularly when such impurities exceed the ICH Q3A/Q3B qualification thresholds and are identified after completion of non-clinical toxicology studies.

Read more
EMA: Discussions on the Revised ERA Guideline

EMA: Discussions on the Revised ERA Guideline

During the second industry stakeholder webinar on the revised guideline on environmental risk assessment (ERA) for medicinal products for human use, the European Medicines Agency (EMA) addressed key implementation challenges observed during the first year of application.
Read more
Previous
Next